ESMO 2022 | Adjuvant HIPEC in locally advanced colon cancer

Alvaro Arjona-Sanchez, MD, Reina Sofia University Hospital, Córdoba, Spain, discusses the results of a Phase III randomized, controlled trial to determine the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally advanced colon cancer. In this study, the addition of HIPEC with mitomycin C to a complete resection improves the locoregional control rate. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.